Kovack Advisors’s Corcept Therapeutics CORT Stock Holding History

Kovack Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,900	Closed	-$207K	–	650
2020 Q4	$207K	Buy	+7,900	New	+$166K	0.03%	514

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Kovack Advisors's CORT Position: Q1 2021 in Review

Kovack Advisors sold out of Corcept Therapeutics (CORT) in Q1 2021, closing a stake of 7,900 shares — an estimated $207K sold.

Kovack Advisors first reported a position in CORT in Q4 2020 and held it in 1 quarter. The position peaked at $207K in Q4 2020. 209 funds tracked by Wall St. Rank hold CORT as of Q1 2021.

Kovack Advisors reported no remaining Corcept Therapeutics position as of Q1 2021 after selling out during the quarter.
Kovack Advisors sold 7,900 Corcept Therapeutics shares in Q1 2021, an estimated $207K.
Kovack Advisors first reported a position in Corcept Therapeutics in Q4 2020 and held it in 1 quarter.
Kovack Advisors's Corcept Therapeutics position peaked at $207K in Q4 2020.
209 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2021.

Based on Kovack Advisors's 13F filing for Q1 2021, filed 4 May 2021.